Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, Genomenon to Integrate Genomic Analysis, Search Engine Platforms

NEW YORK – Genomenon said today it has partnered with Sophia Genetics to incorporate the Mastermind Genomic Search Engine into the Sophia artificial intelligence platform and Alamut Suite for genomic analysis. 

Under the new comarketing and distribution agreement, users will be able to apply both technologies to rapidly access genomic evidence linked to human variants, reducing the time needed to interpret a variant and examine its pathogenicity. 

Sophia, which is headquartered in Saint Sulpice, Switzerland with a US office in Boston, has developed a machine learning tool that helps healthcare professionals detect and characterize genomic variants linked to cancers and hereditary disorders. The firm's Alamut Suite is a genome browser that graphically displays complex genetic information and assesses the pathogenic status of disease mutations. 

"This partnership will help experts better and more quickly assess the impact of accurately detected genomic variants in a clinical context," Gioia Althoff, senior VP of Genomics at Sophia, said in a statement.

Financial details were undisclosed.

"The broader adoption of Genomenon's Mastermind provides significant value to our fast-growing customer base around the world," Genomenon CEO Mike Klein said in a statement. 

Genomenon previously partnered with Congenica to incorporate Mastermind into Congenica's clinical decision support platform. 

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.